Shots:
- The P-ll CALAVI programme involves assessing Calquence + BSC vs BSC as monothx. in patients in a ratio (1:1) hospitalized with respiratory complications of COVID-19 in the ratio of 1:1. The trials conducted in the US and in multiple other countries across the world
- The CALAVI program did not meet its 1EPs of increasing the proportion of patients who remained alive and free of respiratory failure, safety and tolerability profiles were consistent with previous studies
- Calquence is selective inhibitor of BTK, binds covalently to BTK, thereby inhibiting its activity
Click here to read full press release/ article | Ref: AstraZeneca | Image: Red River Radio
The post AstraZenca’s Calquence (acalabrutinib) Fails to Meet its Primary Endpoint in P-II Studies for COVID-19 first appeared on PharmaShots.
